Global HIV News
Prevention 03/02/2012
Africa: No time to 'give up' on HIV-fighting gel
Researchers are optimistic that they are learning as much from their failures as their successes.
Hepatitis 03/02/2012
Idenix announces removal of the partial clinical hold on HCV nucleotide inhibitor, IDX184
The Company's 12-week phase IIb study evaluating IDX184 in combination with pegylated interferon and ribavirin may continue.
Tuberculosis & Malaria 03/02/2012
Global malaria deaths twice as high as previously estimated, IHME study suggests
More than 1.2 million people died from malaria worldwide in 2010, twice the number found in the most recent comprehensive study of the disease.
Pharma Industry 03/02/2012
Merck & Co enjoys healthy quarter but expects flat sales in 2012
Turnover from the HIV drug Isentress (raltegravir) reached $387 million, up 24%.
World Policy 03/02/2012
WHO to issue guidance on hormonal contraceptives and HIV
New findings in 2011 imply a possible increase in HIV infection among women at risk of HIV who use hormonal contraception, or increased transmission to an un-infected partner when a woman is living with HIV and using hormonal contraceptives.
Tuberculosis & Malaria 03/02/2012
Inaccurate TB blood tests commonplace in many TB high-burden countries
17 of 22 highest TB burden countries have these assays on the market.
Access to treatment 02/02/2012
Key generic manufacturer Emcure joins the Medicines Patent Pool
Emcure will be able to manufacture several products licensed to the Pool by Gilead Sciences.
Treatment 02/02/2012
Isentress, Intelence, Prezista regimen goes the distance for HIV treatment veterans
In treatment-experienced patients, an antiretroviral regimen containing raltegravir, etravirine and darunavir/ritonavir shows high efficacy, with a good safety profile.
World Policy 02/02/2012
Media outlets examine Global Fund's future as it enters second decade
Despite its staggering successes, the fund's recent troubles had threatened to overshadow its accomplishments as it prepared to mark a decade as the world's main financier of programs to fight AIDS, tuberculosis and malaria.
Pharma Industry 02/02/2012
Vertex reports fourth quarter and full year 2011 financial results
Successful launch of INCIVEK (telaprevir) for hepatitis C and recent approval of KALYDECO (ivacaftor) for cystic fibrosis position Vertex for continued growth, earnings and cashflow.
Pharma Industry 02/02/2012
Gilead Sciences announces fourth quarter and full year 2011 financial results
Fourth guarter product sales of $2.13 billion, up 11% year over year; Full year 2011 product sales of $8.10 billion, up 10% over 2010; Full year 2011 non-GAAP EPS of $3.86, up 5% over 2010; Full year 2011 operating cash flows of $3.64 billion.
Pharma Industry 02/02/2012
Indian pharma's outlook stable for 2012, says Fitch
Fitch Ratings says its outlook on India's pharmaceutical sector for 2012 remains stable, with earnings prospects remaining positive because of the growing global demand for generics and opportunities provided by patent expiries in developed markets.
Prevention 02/02/2012
For patients with HIV viral load is key in immune response to yellow fever vaccine
In cases where there is travel to a yellow fever-endemic country, neutralizing antibody determination should be performed prior to departure, whatever the time since a previous immunisation, especially in patients with non-controlled HIV RNA at the time of travel or immunisation.
Prevention 02/02/2012
Contraception in HIV prevention trials: injectable hormonal methods more effective?
Women using injectable (hormonal) contraceptives have a significantly lower rate of pregnancy compared to those using oral contraception in a major HIV prevention study.
MSM 02/02/2012
Men who have sex with men may now be the highest-risk group for HIV in Africa, IAVI study suggests
Men who have sex with men may now be at considerably higher risk of acquiring HIV than other at-risk groups such as female sex workers or young people of either sex.
Tuberculosis & Malaria 01/02/2012
South Africa: Africans die of TB, whites die of heart disease
Tuberculosis is the number one killer of Africans in South Africa, according to the latest South Africa Survey, published by the South African Institute of Race Relations in Johannesburg last week.
Tuberculosis & Malaria 01/02/2012
Enrollment complete for REMox TB – global Phase III clinical trial
TB Alliance and partners achieve major milestone in pursuit of first new TB drug in nearly 50 years.
MSM 01/02/2012
Tajikistan: LGBT community stuck in the shadows
Though Tajikistan’s criminal code does not prohibit homosexuality and homosexual relationships, LGBT individuals are still singled out for persecution by some officials.
World Policy 01/02/2012
UNAIDS Reference Group statement on the Global Fund and the crisis of HIV funding
The Global Fund and the crisis of HIV funding — a severe setback for HIV and human rights.
Hepatitis 01/02/2012
Stem cells could drive hepatitis research forward
By creating liver-like cells, scientists can study why people respond differently to the disease.
More...
